pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›ICOTYDE
drug
save

ICOTYDE

updated 6mo ago
by Janssen Biotech Inc
community read0 votes

🐶 often sniffed alongside

top 4
  • drugicotrokinra hydrochloride4 co-mentions · 1 sources
  • tagApproval4 co-mentions · 1 sources
  • companyJanssen Biotech Inc2 co-mentions · 1 sources
  • tagSmall Molecule2 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

News(10)

  • J&J and Protagonist’s Icotyde improves psoriatic arthritis but AbbVie’s Skyrizi likely to reign
    A Phase 3 trial showed that Johnson & Johnson and Protagonist Therapeutics’ oral therapy Icotyde improved psoriatic arthritis symptoms but AbbVie’s injectable is likely to hold court based on highe…
    biospace · 10d ago
  • Argenx inks $1.15B Unnatural Products buyout to expand in oral peptides
    Argenx has struck a deal to acquire Unnatural Products for $550 million upfront, snapping up the Merck & Co.- and Novartis-partnered biotech to add oral peptide capabilities.
    fiercebiotech · 10d ago
  • China's InventisBio delivers competitive TYK2 data in phase 3 psoriasis win
    A phase 3 trial of InventisBio’s nomelcitinib has hit its primary endpoint, delivering evidence that the TYK2 inhibitor can hold its own against rival psoriasis drugs.
    fiercebiotech · 17d ago
  • 5 new drug launches that defied industry expectations
    A clearly superior clinical profile, reasonable pricing and easy access has helped a handful of recently approved therapies achieve impressive launches.
    biospace · 22d ago
  • Another autoimmune CAR-T death; Treasury zeroes in on China deals
    A patient who received Bristol Myers’ zola-cel died 44 days later. Elsewhere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis pill.
    biopharma_dive · 24d ago
  • Gilead to pay $1.3B upfront for PepStar’s oral IL-23 challenger to J&J’s Icotyde
    Gilead has struck a deal to acquire PepStar Therapeutics’ oral IL-23 receptor inhibitor program for $1.275 billion, positioning itself as a would-be challenger to Johnson & Johnson’s Icotyde across…
    fiercebiotech · 27d ago
  • Chutes & Ladders—Bausch + Lomb's returning CEO Saunders exits again
    Bausch + Lomb CEO Brent Saunders is making a second exit from the eye health company, as the president of parent Bausch Health steps in temporarily. Plus, Paragon Labs is buying out Apogee talent a…
    fiercebiotech · 1mo ago
  • J&J’s innovative medicines carried Q3 as medtech disappoints, but newer medicines absent
    While innovative medicine supported Johnson & Johnson’s “in line” earnings for the third quarter of 2026, investors were disappointed to see older medicines carrying the bag.
    biospace · 1mo ago
  • 6 immunology targets to sustain a mammoth I&I market
    Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
    biospace · 1mo ago
  • 5 biotechs braving the commercial waters with product launches
    A growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving capital markets,” according to Jefferies’ Andrew Tsai.
    biospace · 2mo ago
view all news mentions →
brand
ICOTYDE
generic
ICOTROKINRA HYDROCHLORIDE
Data sources
ClinicalTrials.gov
last refreshed 6h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?